NCT06980038 2026-03-19
Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer
National Cancer Institute (NCI)
Phase 2 Recruiting
National Cancer Institute (NCI)
National Cancer Institute (NCI)
University of Michigan Rogel Cancer Center
Alliance for Clinical Trials in Oncology
Diakonos Oncology Corporation
Diakonos Oncology Corporation
University of Calgary
University of British Columbia
University of Rome Tor Vergata